Novavax

<p>Novavax, Inc. is an American <a href="/facts/Biotechnology/8eFnI6FB">biotechnology</a> company based in <a href="/facts/Gaithersburg%2c_Maryland/NU2ItqFm">Gaithersburg, Maryland</a>, that develops <a href="/facts/Vaccines/QcXzLug2">vaccines</a> to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for <a href="/facts/Influenza/nWuFzh6L">influenza</a> and <a href="/facts/Respiratory_syncytial_virus/ckD64j8a">respiratory syncytial virus</a> (RSV), as well as <a href="/facts/Ebola/9e8kyCVy">Ebola</a> and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its <a href="/facts/NVX-CoV2373/bY4ByGQz">NVX-CoV2373 vaccine</a> for <a href="/facts/COVID-19/YsUgvsaX">COVID-19</a>.
</p><p>The COVID-19 vaccine <a href="/facts/Novavax_COVID-19_vaccine/bY4ByGQz">Nuvaxovid</a> was approved in the European Union at the end of 2021, and in Canada in February 2022, as the fifth vaccine against COVID-19, following <a href="/facts/Pfizer%25E2%2580%2593BioNTech_COVID-19_vaccine/T0AYCJ9p">Pfizer/BioNTech</a>, <a href="/facts/Moderna/tjjjJqNs">Moderna</a>, <a href="/facts/Janssen_COVID-19_vaccine/a6ePrE7M">Janssen</a> and <a href="/facts/Oxford%25E2%2580%2593AstraZeneca_COVID-19_vaccine/1DF8upN8">AstraZeneca</a>.
</p>

Novavax open-in-new

Novavax